Study of SG in breast cancer with brain metastases
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This study follows patients with breast cancer that has spread to the brain and who have already received the drug Sacituzumab Govitecan (SG). The goal is to learn how well SG works in real-world settings and to see how patients are doing over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with breast cancer (confirmed by a biopsy).
- The breast cancer has spread to your brain – there is no limit on how many or how big the spots are.
- You have already been treated with the drug Sacituzumab Govitecan (SG) in the past, no matter how many doses you received.
- You do not have any other active cancer (other than breast cancer) in the last 5 years.
- Your health is stable enough that you can take part in the study’s follow-up (clinic visits, phone calls, or medical record checks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, NBQ72S, for people with breast cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastasis). It aims to see if the drug is safe and helpful for these patients.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
This trial tests whether a different chemotherapy drug, called sacituzumab govitecan (SG), can help people with ER+/HER2-low metastatic breast cancer who have already been treated with trastuzumab deruxtecan (T-DXd). It also looks at genetic markers in your tumor to predict who might benefit from SG.
This trial tests adding the drugs sacituzumab govitecan and zimberelimab to targeted radiation therapy for people with triple-negative breast cancer that has spread to the brain. The goal is to see if this combination helps control the cancer longer.
This study tests whether giving the drug sacituzumab govitecan together with atropine reduces side effects and improves tolerability in people with advanced breast cancer. You may be eligible if you have either triple-negative or hormone receptor-positive, HER2-negative breast cancer that hasn't responded to previous treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.